Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H22Cl2N6OS |
InChIKeyLHMJTCJXGOQGEX-UHFFFAOYSA-N |
CAS Registry3034411-38-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 01 Aug 2022 |